WO1999040932A1 - Mixed micellar pharmaceutical delivery system and method of preparation - Google Patents

Mixed micellar pharmaceutical delivery system and method of preparation Download PDF

Info

Publication number
WO1999040932A1
WO1999040932A1 PCT/CA1999/000106 CA9900106W WO9940932A1 WO 1999040932 A1 WO1999040932 A1 WO 1999040932A1 CA 9900106 W CA9900106 W CA 9900106W WO 9940932 A1 WO9940932 A1 WO 9940932A1
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
insulin
acid
absorption enhancing
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1999/000106
Other languages
English (en)
French (fr)
Other versions
WO1999040932A9 (en
Inventor
Pankaj Modi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generex Pharmaceuticals Inc
Original Assignee
Generex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharmaceuticals Inc filed Critical Generex Pharmaceuticals Inc
Priority to AU25053/99A priority Critical patent/AU750197B2/en
Priority to NZ506024A priority patent/NZ506024A/en
Priority to JP2000531183A priority patent/JP4499282B2/ja
Priority to EP99904638A priority patent/EP1053011B1/en
Priority to DK99904638T priority patent/DK1053011T3/da
Priority to DE69937546T priority patent/DE69937546T2/de
Publication of WO1999040932A1 publication Critical patent/WO1999040932A1/en
Publication of WO1999040932A9 publication Critical patent/WO1999040932A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • mixed micellar pharmaceutical formulation is suitably diluted to avoid irritation of the nasal passages.
  • the mixed micellar formulation is formed by sonication of the aqueous micellar pharmaceutical agent composition in the presence of lecithin.
  • compositions of the present invention require that the pharmaceutical formulation be in mixed micellar form.
  • the first micellar solution may be made by adding a buffer solution to powdered insulin, and then stirring until the powder is dissolved and a clear solution is obtained.
  • a typical buffer solution is an aqueous solution of sodium salicylate and sodium lauryl sulphate and disodium edetate. Typical concentration of sodium salicylate and sodium lauryl sulphate in the aqueous solution are about 3 to 20 wt . /wt . % of each compound in the solution.
  • insulin is present in the micellar solution in an amount which will give a concentration of about 2 to 4 wt . /wt . % of the final formulation.
  • the volunteers received 10 units insulin by injection (regular fast acting insulin, available from Eli Lilly) .
  • the volunteers received 100 units (1 mL volume per drop, approximately 20 drops) of the above-prepared oral insulin (10 times the injection dose) .
  • blood glucose levels were monitored every 15 minutes by Bayer's Glucometer Elite.
  • Oral insulin (50 units) was formulated using only alkali metal lauryl sulphate (5% by wt) . Blood glucose levels were monitored every 15 minutes using Bayer's glucometer Elite for 3 hours and the average results for four volunteers are shown in Table VI .
  • micellar oral insulin 50 units was formulated using alkali metal lauryl sulphate and sodium salicylate (both 4.4% by wt . ) and alkali metal edetate (2.2% by wt) with Phospholipon-H (10 mg) and tested on healthy volunteers .
  • the method involved mixing the sodium lauryl sulphate, sodium salicylate and alkali metal edetate with water in a beaker with a magnetic stirrer at medium speed until the ingredients were dissolved, to form buffer solution. Insulin powder was placed in a beaker and to this powder was added the buffer solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
PCT/CA1999/000106 1998-02-10 1999-02-05 Mixed micellar pharmaceutical delivery system and method of preparation Ceased WO1999040932A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU25053/99A AU750197B2 (en) 1998-02-10 1999-02-05 Mixed micellar pharmaceutical delivery system and method of preparation
NZ506024A NZ506024A (en) 1998-02-10 1999-02-05 Mixed micellar pharmaceutical delivery system and method of preparation
JP2000531183A JP4499282B2 (ja) 1998-02-10 1999-02-05 混合ミセル状薬剤の移送システム及び調製方法
EP99904638A EP1053011B1 (en) 1998-02-10 1999-02-05 Mixed micellar pharmaceutical delivery system and method of preparation
DK99904638T DK1053011T3 (da) 1998-02-10 1999-02-05 System i form af blandede miceller til indgivelse af lægemiddelstoffer og fremgangsmåde til fremstilling heraf
DE69937546T DE69937546T2 (de) 1998-02-10 1999-02-05 Mischmizell-arzneistoffverabreichungssystem und verfahren zu dessen herstellung

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/021,114 US6017545A (en) 1998-02-10 1998-02-10 Mixed micellar delivery system and method of preparation
US09/021,114 1998-02-10
US09/216,733 US6231882B1 (en) 1998-02-10 1998-12-21 Mixed micellar delivery system and method of preparation
US09/216,733 1998-12-21

Publications (2)

Publication Number Publication Date
WO1999040932A1 true WO1999040932A1 (en) 1999-08-19
WO1999040932A9 WO1999040932A9 (en) 2000-03-30

Family

ID=21802420

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000106 Ceased WO1999040932A1 (en) 1998-02-10 1999-02-05 Mixed micellar pharmaceutical delivery system and method of preparation

Country Status (12)

Country Link
US (2) US6017545A (https=)
EP (1) EP1053011B1 (https=)
JP (1) JP4499282B2 (https=)
AT (1) ATE378062T1 (https=)
AU (1) AU750197B2 (https=)
BR (1) BR9804295A (https=)
DE (1) DE69937546T2 (https=)
DK (1) DK1053011T3 (https=)
ES (1) ES2296380T3 (https=)
NZ (1) NZ506024A (https=)
PT (1) PT1053011E (https=)
WO (1) WO1999040932A1 (https=)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000018371A1 (en) * 1998-09-27 2000-04-06 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
WO2000037051A1 (en) * 1998-12-21 2000-06-29 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
WO2000037052A1 (en) * 1998-12-21 2000-06-29 Generex Pharmaceuticals Inc. Pulmonary drug delivery
WO2000037053A1 (en) * 1998-12-21 2000-06-29 Generex Pharmaceuticals Inc. Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles
WO2000056291A1 (en) * 1999-03-19 2000-09-28 Generex Pharmaceuticals Inc. Pharmaceutical solubilized in aerosol propellant
WO2001015666A1 (en) * 1999-08-31 2001-03-08 Generex Pharmaceuticals Inc. Mixed micellar pharmaceutical delivery system and method of preparation
WO2001017506A1 (en) * 1999-09-07 2001-03-15 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
WO2001039794A1 (fr) * 1999-11-30 2001-06-07 Oao 'quantum Satis' Medicament a usage peroral contenant de l'insuline et procede de fabrication correspondant
WO2001087268A1 (en) * 2000-05-19 2001-11-22 Generex Pharmaceuticals Inc. Micellar pharmaceutical compositions for buccal and pulmonary application
WO2001066085A3 (en) * 2000-03-06 2002-04-11 Generex Pharm Inc Micellar pharmaceutical compositions for buccal and pulmonary application
WO2001072278A3 (en) * 2000-03-30 2002-04-11 Generex Pharm Inc Method for administering insulin to the buccal region
WO2002051380A1 (de) 2000-12-22 2002-07-04 Audit Institute For Medical Services And Quality Assurance Gmbh Neue pharmazeutische zusammensetzung von wasserlöslichen oder schwer wasserlöslichen wirkstoffen
EP1230917A1 (de) * 2001-02-08 2002-08-14 Vectron Therapeutics AG Invasomen zur Therapie von Erkrankungen, ihre Herstellung und Verwendung
AU763251B2 (en) * 1998-02-10 2003-07-17 Generex Pharmaceuticals Inc. Mixed micellar pharmaceutical delivery system and method for preparation
EP1338272A1 (en) * 1998-12-21 2003-08-27 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate
JP2006517190A (ja) * 2002-12-24 2006-07-20 イーゲー スプリューテクニーク ゲーエムベーハー ウント ツェーオー．カーゲー 界面活性物質としてレシチンを含む投与エーロゾル
US7087215B2 (en) 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
AU2006200276B2 (en) * 1998-12-21 2007-11-29 Generex Pharmaceuticals Inc. Micellar pharmaceutical compositions for buccal and pulmonary application
CN115154427A (zh) * 2022-08-15 2022-10-11 保定冀中药业有限公司 一种提高四黄止痢颗粒治疗湿热泻痢效果的制备方法
EP3893847A4 (en) * 2018-12-10 2022-11-02 Halo Science LLC STABLE FORMULATIONS OF ANESTHETICS AND RELATED DOSAGE FORMS

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6635617B1 (en) * 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
US6436367B1 (en) * 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6350432B1 (en) * 1999-03-19 2002-02-26 Generex Pharmaceuticals Incorporated Pressurized container having an aerosolized pharmaceutical composition
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
EP2206720A1 (en) * 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001287628A1 (en) * 2000-07-17 2002-01-30 Hansa Medical Ab Antimicrobial agent
ES2171147B1 (es) * 2001-02-06 2003-12-16 Esteve Labor Dr Preparacion para usos veterinarios.
US20060062855A1 (en) * 2001-02-27 2006-03-23 Bell Steve J D Therapeutic calcium phosphate particles for use in inhibiting expression of a gene
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
EP2261250B1 (en) * 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1369113B1 (en) * 2002-06-06 2006-11-22 CHIESI FARMACEUTICI S.p.A. Solubilisation of drugs in HFA propellant by means of emulsions
US20040115226A1 (en) * 2002-12-12 2004-06-17 Wenji Li Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20050238632A1 (en) * 2004-04-23 2005-10-27 Alburty David S Propellant formulations
WO2005105040A2 (en) * 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
KR20050104152A (ko) * 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물
CA2586035A1 (en) 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles in use for aesthetic or cosmetic medicine, and methods of manufacture and use
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
CN101309668A (zh) * 2005-11-30 2008-11-19 健乐克斯医药公司 经口吸收的药物制剂和用药方法
US20070264130A1 (en) * 2006-01-27 2007-11-15 Phluid, Inc. Infusion Pumps and Methods for Use
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20080146672A1 (en) * 2006-12-08 2008-06-19 Denton Marcia Marye Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
US8986253B2 (en) * 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
WO2009143188A2 (en) * 2008-05-19 2009-11-26 Diperna Paul M Disposable pump reservoir and related methods
US8408421B2 (en) * 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) * 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
GB0904942D0 (en) * 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
US20120201857A1 (en) * 2010-03-17 2012-08-09 Pankaj Modi Transdermal delivery system for therapeutics
DE102010015350A1 (de) 2010-04-16 2011-10-20 Michael Zimmermann Vaginalapplikator
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026302A1 (en) * 1993-05-12 1994-11-24 Genentech, Inc. Stable liquid compositions of gamma interferon
WO1996019197A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol formulations of peptides and proteins
WO1996036352A1 (en) * 1995-05-16 1996-11-21 Pankaj Modi Liquid formulations for proteinic pharmaceuticals comprising at least 2 absorption enhancers

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32393A (en) * 1861-05-21 Harrison Williams Stop-motion for drawing-frames
US2055083A (en) * 1932-07-13 1936-09-22 Winthrop Chem Co Inc Pharmaceutical preparation
DE1792410B2 (de) 1967-09-01 1980-03-13 Apoteksvarucentralen Vitrum Apotekareaktiebolaget, Stockholm Arzneimittelzubereitung zur intravenösen Injektion
US4464363A (en) * 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
DE3171774D1 (en) * 1980-03-31 1985-09-19 Teijin Ltd Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
US4900730A (en) * 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
US4849405A (en) * 1984-05-09 1989-07-18 Synthetic Blood Corporation Oral insulin and a method of making the same
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4963526A (en) * 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
JPS61267528A (ja) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
EP0200383A3 (en) * 1985-04-15 1987-09-02 Eli Lilly And Company An improved method for administering insulin
US4822773A (en) * 1985-06-28 1989-04-18 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4973579A (en) * 1985-06-28 1990-11-27 Merck & Co., Inc. Enhancment of absorption of drugs from gastrointestinal tract using choline ester salts
US4729989A (en) * 1985-06-28 1988-03-08 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4963556A (en) * 1985-08-16 1990-10-16 Merck & Co., Inc. Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US4692441A (en) * 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
KR0157428B1 (ko) * 1989-02-17 1998-11-16 알렌 불룸 비 전달용 지질부형제와 그 사용법
US5109118A (en) * 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
CA2033725C (en) * 1990-01-24 2001-05-29 Folker Pittrof Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
US5230884A (en) * 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
US5292489A (en) * 1991-06-24 1994-03-08 Alliedsignal Inc. Ternary silicon-rare earth nitrides and process for their preparation
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5482706A (en) * 1992-04-17 1996-01-09 Takeda Chemical Industries, Ltd. Transmucosal therapeutic composition
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
FI963066A7 (fi) * 1994-02-04 1996-09-30 Lipocore Holding Ab Lipofiiliset kantoainevalmisteet
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
US5451569A (en) * 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5574017A (en) * 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026302A1 (en) * 1993-05-12 1994-11-24 Genentech, Inc. Stable liquid compositions of gamma interferon
WO1996019197A1 (en) * 1994-12-22 1996-06-27 Astra Aktiebolag Aerosol formulations of peptides and proteins
WO1996036352A1 (en) * 1995-05-16 1996-11-21 Pankaj Modi Liquid formulations for proteinic pharmaceuticals comprising at least 2 absorption enhancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMAMOTO A ET AL: "Pulmonary absorption enhancement of peptides by absorption enhancers and protease inhibitors", JOURNAL OF CONTROLLED RELEASE, vol. 41, no. 1, 1 August 1996 (1996-08-01), pages 57-67, XP004037571 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU763251B2 (en) * 1998-02-10 2003-07-17 Generex Pharmaceuticals Inc. Mixed micellar pharmaceutical delivery system and method for preparation
WO2000018371A1 (en) * 1998-09-27 2000-04-06 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
AU783431B2 (en) * 1998-12-21 2005-10-27 Generex Pharmaceuticals Inc. Pharmaceutical compositions for buccal and pulmonary application
AU2006200276B2 (en) * 1998-12-21 2007-11-29 Generex Pharmaceuticals Inc. Micellar pharmaceutical compositions for buccal and pulmonary application
US6451286B1 (en) 1998-12-21 2002-09-17 Generex Pharmaceuticals Incorporated Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds
WO2000037051A1 (en) * 1998-12-21 2000-06-29 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
WO2000037053A1 (en) * 1998-12-21 2000-06-29 Generex Pharmaceuticals Inc. Large molecule drug delivery system using aerosolized membrane-mimetic amphiphiles
WO2000037052A1 (en) * 1998-12-21 2000-06-29 Generex Pharmaceuticals Inc. Pulmonary drug delivery
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
EP1338272A1 (en) * 1998-12-21 2003-08-27 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate
US7087215B2 (en) 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
AU766745B2 (en) * 1999-03-19 2003-10-23 Generex Pharmaceuticals Inc. Pharmaceutical solubilized in aerosol propellant
WO2000056291A1 (en) * 1999-03-19 2000-09-28 Generex Pharmaceuticals Inc. Pharmaceutical solubilized in aerosol propellant
JP2003508421A (ja) * 1999-08-31 2003-03-04 ジェネレクス ファーマシューティカルズ インコーポレイテッド 混合ミセル状薬剤の送達システム及び調製方法
WO2001015666A1 (en) * 1999-08-31 2001-03-08 Generex Pharmaceuticals Inc. Mixed micellar pharmaceutical delivery system and method of preparation
WO2001017506A1 (en) * 1999-09-07 2001-03-15 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
WO2001039794A1 (fr) * 1999-11-30 2001-06-07 Oao 'quantum Satis' Medicament a usage peroral contenant de l'insuline et procede de fabrication correspondant
US6770276B1 (en) 1999-11-30 2004-08-03 Otkrytoe Aktsionernoe Obschestvo “Quantum Satis” Insulin-containing medicament for peroral application and method for the production thereof
WO2001066085A3 (en) * 2000-03-06 2002-04-11 Generex Pharm Inc Micellar pharmaceutical compositions for buccal and pulmonary application
JP2003525891A (ja) * 2000-03-06 2003-09-02 ジェネレクス ファーマシューティカルズ インコーポレイテッド 口腔及び経肺投与用薬学的組成物
WO2001072278A3 (en) * 2000-03-30 2002-04-11 Generex Pharm Inc Method for administering insulin to the buccal region
WO2001087268A1 (en) * 2000-05-19 2001-11-22 Generex Pharmaceuticals Inc. Micellar pharmaceutical compositions for buccal and pulmonary application
JP2003533469A (ja) * 2000-05-19 2003-11-11 ジェネレクス ファーマシューティカルズ インコーポレイテッド 口腔及び経肺投与用ミセル薬学的組成物
WO2002051380A1 (de) 2000-12-22 2002-07-04 Audit Institute For Medical Services And Quality Assurance Gmbh Neue pharmazeutische zusammensetzung von wasserlöslichen oder schwer wasserlöslichen wirkstoffen
EP1230917A1 (de) * 2001-02-08 2002-08-14 Vectron Therapeutics AG Invasomen zur Therapie von Erkrankungen, ihre Herstellung und Verwendung
WO2002062316A1 (de) * 2001-02-08 2002-08-15 Vectron Therapeutics Ag Invasomen zur therapie von erkrankungen, ihre herstellung und verwendung
JP2006517190A (ja) * 2002-12-24 2006-07-20 イーゲー スプリューテクニーク ゲーエムベーハー ウント ツェーオー．カーゲー 界面活性物質としてレシチンを含む投与エーロゾル
EP3893847A4 (en) * 2018-12-10 2022-11-02 Halo Science LLC STABLE FORMULATIONS OF ANESTHETICS AND RELATED DOSAGE FORMS
CN115154427A (zh) * 2022-08-15 2022-10-11 保定冀中药业有限公司 一种提高四黄止痢颗粒治疗湿热泻痢效果的制备方法
CN115154427B (zh) * 2022-08-15 2023-07-11 保定冀中药业有限公司 一种提高四黄止痢颗粒治疗湿热泻痢效果的制备方法

Also Published As

Publication number Publication date
DK1053011T3 (da) 2008-03-25
JP4499282B2 (ja) 2010-07-07
EP1053011A1 (en) 2000-11-22
AU2505399A (en) 1999-08-30
AU750197B2 (en) 2002-07-11
NZ506024A (en) 2002-02-01
US6017545A (en) 2000-01-25
EP1053011B1 (en) 2007-11-14
DE69937546T2 (de) 2008-05-29
JP2003522096A (ja) 2003-07-22
PT1053011E (pt) 2008-02-14
ES2296380T3 (es) 2008-04-16
US6231882B1 (en) 2001-05-15
WO1999040932A9 (en) 2000-03-30
ATE378062T1 (de) 2007-11-15
DE69937546D1 (de) 2007-12-27
BR9804295A (pt) 2000-03-28

Similar Documents

Publication Publication Date Title
US6231882B1 (en) Mixed micellar delivery system and method of preparation
US6221378B1 (en) Mixed micellar delivery system and method of preparation
US6432383B1 (en) Method for administering insulin
US6312665B1 (en) Aerosol formulations for buccal and pulmonary application
US6350458B1 (en) Mixed micellar drug deliver system and method of preparation
AU783431B2 (en) Pharmaceutical compositions for buccal and pulmonary application
US20100203105A1 (en) Method for administering insulin to the buccal region
US6436367B1 (en) Aerosol formulations for buccal and pulmonary application
NZ522524A (en) Micellar pharmaceutical compositions for buccal and pulmonary application
WO2001072278A2 (en) Method for administering insulin to the buccal region
EP1338272A1 (en) Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate
CA2229286C (en) Mixed micellar delivery system and method of preparation
AU2002301424B2 (en) Mixed micellar pharmaceutical delivery system and method of preparation
AU763251B2 (en) Mixed micellar pharmaceutical delivery system and method for preparation
MXPA00007802A (en) Mixed micellar pharmaceutical delivery system and method of preparation
AU2003259466A1 (en) Methods of administering and enhancing absorption of pharmaceutical agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: THE PAGES OF THE DESCRIPTION, CLAIMS, AND INTERNATIONAL SEARCH REPORT REPLACED BY CORRECT PAGES; DUE TO A SCANNING ERROR DURING THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWE Wipo information: entry into national phase

Ref document number: 506024

Country of ref document: NZ

Ref document number: 25053/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999904638

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/007802

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1999904638

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 25053/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1999904638

Country of ref document: EP